Phenotyping Core

表型核心

• 批准号: 9924582
• 负责人: Lijun Xia
• 金额: $ 44.85万
• 依托单位: OKLAHOMA MEDICAL RESEARCH FOUNDATION
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至 2021-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9924582
• 关键词: Accountability; Advisory Committees; Biology; Blood; Blood Cell Count; Blood Cells; Blood Chemical Analysis; Blood Vessels; Cardiovascular Diseases; Cardiovascular system; Centers of Research Excellence; Chemicals; Chemistry; Clinical; Complex; Consultations; Disease; Disease model; Doctor of Medicine; Doctor of Philosophy; Effectiveness; Functional disorder; Funding; Future; Gene Targeting; Goals; Grant; Interdisciplinary Study; International; Leadership; Molecular; Mus; Pathology; Phase; Phenotype; Physicians; Pilot Projects; Procedures; Publications; Reporter; Research; Research Personnel; Research Project Grants; Resources; Sampling; Scientist; Services; Structure; Surveys; System; Technical Expertise; Techniques; Technology; Testing; Tissues; Training; Ultrasonography; Universities; Urine; automated analysis; cardiovascular imaging; catalyst; cost; design; experience; follow-up; genetic analysis; genetic resource; heart function; hemodynamics; imaging system; instrument; instrumentation; member; metabolic phenotype; mouse genetics; mouse model; novel; programs; recruit; response; skills; success; tool

PROJECT SUMMARY: The Cardiovascular Phenotyping Core was added during Phase II of the OMRF “Interdisciplinary Research in Vascular Biology” COBRE grant in response to growing demand from COBRE investigators for scientific and technical expertise in developing cardiovascular disease models and conducting specialized pathophysiological tests. The Phase III Cardiovascular Phenotyping Core objective is to expand resources, services, and training available to COBRE and non-COBRE investigators for establishing precise cardiovascular and metabolic phenotypes for their genetically-altered mice. All COBRE investigators use gene- targeted mice and mouse models of cardiovascular disease as major research approaches to elucidate the molecular mechanisms of disease and generate novel discoveries in cardiovascular biology. This year, we significantly strengthened the Core capabilities by purchasing a cutting-edge VisualSonics Vevo-2100 Ultrasound Imaging System. With institutional support, we upgraded our Hemavet analyzer for blood cell count and differentials, and purchased a new Catalyst Dx Chemistry Analyzer that permits automated analysis of a broad spectrum of clinical chemical parameters of mouse blood and urine samples. The Core will provide a centralized system for accessing this state-of-the-art technology for evaluating complex cardiovascular disease pathologies to COBRE and non-COBRE investigators and will be guided by 3 specific aims: 1) Provide services of echocardiographic and Doppler imaging of cardiovascular structures and functions of genetically modified mice using Vevo-2100 system; 2) Provide consultation, training, genetic resources, and special instrumentation for general phenotyping, including peripheral blood cell and chemistry analyses, and sophisticated mouse cardiovascular procedures/disease models. The Core will maintain colonies of valuable mouse genetic tools (e.g. inducible or tissue-specific Cre or reporter lines) for genetic analysis of cardiovascular phenotypes; 3) Develop Core into sustainable facility that continues to provide services to COBRE and external cardiovascular investigators after Phase III funding. To achieve the Aims, the Core will provide COBRE and external investigators: 1) direct ultrasound imaging services, 2) technical training to use validated cardiovascular phenotyping techniques and instruments, 3) service for procedures requiring highly specialized skills, and 4) mouse genetic tools. A Core Coordinator will be designated for service requests and conduct regular surveys of end users to evaluate quality, turn-around, service costs, and training effectivness: this will be evaluated quarterly by Core Directors and annually by the External Advisory Committee, providing accountability for the Core's success. The Aims will be implemented under highly qualified director/co-director leadership and dedicated expert technical staff. By offering unique training and collaborative opportunities, we expect to develop this Core into a sustainable facility and further nurture establishment of an internationally- recognized center of excellence.

项目摘要：在 OMRF 第二阶段添加了心血管表型分析核心 “血管生物学跨学科研究”COBRE 资助，以满足 COBRE 不断增长的需求 研究人员在开发心血管疾病模型和进行研究方面具有科学和技术专业知识 第三阶段心血管表型分析的核心目标是扩大专门的病理生理学测试。 COBRE 和非 COBRE 调查人员可利用的资源、服务和培训，以建立精确的 所有 COBRE 研究人员都使用基因改造小鼠的心血管和代谢表型。 靶向小鼠和心血管疾病小鼠模型作为阐明心血管疾病的主要研究方法 今年，我们在心血管生物学领域取得了新的发现。 通过购买尖端的 VisualSonics Vevo-2100 显着增强了核心能力 在机构支持下，我们升级了 Hemavet 血细胞计数分析仪。 和差异，并购买了新的 Catalyst Dx 化学分析仪，可以自动分析 核心将提供小鼠血液和尿液样本的广泛临床化学参数。 用于评估复杂心血管疾病的最先进技术的集中式系统 向 COBRE 和非 COBRE 研究人员提供病理学信息，并将以 3 个具体目标为指导：1) 提供 心血管结构和遗传功能的超声心动图和多普勒成像服务 使用Vevo-2100系统改造小鼠；2）提供咨询、培训、遗传资源和特殊 一般表型分析仪器，包括外周血细胞和化学分析，以及 复杂的小鼠心血管手术/疾病模型将维持有价值的群体。 用于遗传分析的小鼠遗传工具（例如诱导型或组织特异性 Cre 或报告系） 3) 将核心发展成为可持续设施，继续为以下人群提供服务 在获得第三阶段资助后，COBRE 和外部心血管研究人员将实现这些目标。 为 COBRE 和外部研究者提供：1）直接超声成像服务，2）使用技术培训 经过验证的心血管表型分析技术和仪器，3) 为要求高的程序提供服务 专业技能，以及 4) 小鼠遗传工具将被指定负责服务请求和 对最终用户进行定期调查，以评估质量、周转时间、服务成本和培训效果： 核心董事将每季度对此进行评估，外部咨询委员会将每年对此进行评估，提供 核心的成功责任将在高素质的董事/联合董事的领导下实施。 通过提供独特的培训和协作机会，我们的领导力和敬业的专家技术人员。 期望将该核心发展成为一个可持续的设施，并进一步培育建立一个国际化的 公认的卓越中心。